(1)        Lake, D. F.; Faigel, D. O. The Emerging Role of QSOX1 in Cancer. Antioxid. Redox Signal. 2014, 21 (3), 485–496. https://doi.org/10.1089/ars.2013.5572.

(2)        Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R. L.; Torre, L. A.; Jemal, A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2018, 68 (6), 394–424. https://doi.org/10.3322/caac.21492.

(3)        Ploeg, M.; Aben, K. K. H.; Kiemeney, L. A. The Present and Future Burden of Urinary Bladder Cancer in the World. World J. Urol. 2009, 27 (3), 289–293. https://doi.org/10.1007/s00345-009-0383-3.

(4)        Boston, 677 Huntington Avenue; Ma 02115 +1495‑1000. Cancer is on the rise in developing countries https://www.hsph.harvard.edu/news/magazine/shadow-epidemic/ (accessed Mar 28, 2019).

(5)        Antoni, S.; Ferlay, J.; Soerjomataram, I.; Znaor, A.; Jemal, A.; Bray, F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur. Urol. 2017, 71 (1), 96–108. https://doi.org/10.1016/j.eururo.2016.06.010.

(6)        Jason A. Efstathiou; Zietman, A. L. Blader Cancer. In Clinical Radiation Oncology; 2016.

(7)        Leite, R. de C. H.; Holanda, C. M. de C. X.; Medeiros, P. J. de. Schistosomiasis and Urothelial Bladder Carcinoma. Case Rep. Clin. Med. 2014, 2014. https://doi.org/10.4236/crcm.2014.39116.

(8)        Frantzi, M.; Latosinska, A.; Flühe, L.; Hupe, M. C.; Critselis, E.; Kramer, M. W.; Merseburger, A. S.; Mischak, H.; Vlahou, A. Developing Proteomic Biomarkers for Bladder Cancer: Towards Clinical Application. Nat. Rev. Urol. 2015, 12 (6), 317–330. https://doi.org/10.1038/nrurol.2015.100.

(9)        Rosser, C. J.; Urquidi, V.; Goodison, S. Urinary Biomarkers of Bladder Cancer: An Update and Future Perspectives. Biomark. Med. 2013, 7 (5), 779–790. https://doi.org/10.2217/bmm.13.73.

(10)      Santoni, G.; Morelli, M. B.; Amantini, C.; Battelli, N. Urinary Markers in Bladder Cancer: An Update. Front. Oncol. 2018, 8. https://doi.org/10.3389/fonc.2018.00362.

(11)      Leiblich, A. Recent Developments in the Search for Urinary Biomarkers in Bladder Cancer. Curr. Urol. Rep. 2017, 18 (12), 100. https://doi.org/10.1007/s11934-017-0748-x.

(12)      Deb, B.; Kumar, P. Biomarkers for Bladder Cancer: Present Challenges and Recent Developments. J. Cancer Res. Treat. 2018, 6 (2), 34–38. https://doi.org/10.12691/jcrt-6-2-2.

(13)      Grossman, H. B.; Soloway, M.; Messing, E.; Katz, G.; Stein, B.; Kassabian, V.; Shen, Y. Surveillance for Recurrent Bladder Cancer Using a Point-of-Care Proteomic Assay. JAMA 2006, 295 (3), 299–305. https://doi.org/10.1001/jama.295.3.299.

(14)      Budman, L. I.; Kassouf, W.; Steinberg, J. R. Biomarkers for Detection and Surveillance of Bladder Cancer. Can. Urol. Assoc. J. 2008, 2 (3), 212–221.

(15)      Hutterer, G. C.; Karakiewicz, P. I.; Zippe, C.; Lüdecke, G.; Boman, H.; Sanchez-Carbayo, M.; Casella, R.; Mian, C.; Friedrich, M. G.; Eissa, S.; et al. Urinary Cytology and Nuclear Matrix Protein 22 in the Detection of Bladder Cancer Recurrence Other than Transitional Cell Carcinoma. BJU Int. 2008, 101 (5), 561–565. https://doi.org/10.1111/j.1464-410X.2007.07352.x.

(16)      Ecke, T. H.; Weiß, S.; Stephan, C.; Hallmann, S.; Arndt, C.; Barski, D.; Otto, T.; Gerullis, H. UBC®Rapid Test-A Urinary Point-of-Care (POC) Assay for Diagnosis of Bladder Cancer with a Focus on Non-Muscle Invasive High-Grade Tumors: Results of a Multicenter-Study. Int. J. Mol. Sci. 2018, 19 (12). https://doi.org/10.3390/ijms19123841.

(17)      Alvarez, A.; Lokeshwar, V. B. Bladder Cancer Biomarkers: Current Developments and Future Implementation. Curr. Opin. Urol. 2007, 17 (5), 341–346. https://doi.org/10.1097/MOU.0b013e3282c8c72b.

(18)      Rudolf, J.; Pringle, M. A.; Bulleid, N. J. Proteolytic Processing of QSOX1A Ensures Efficient Secretion of a Potent Disulfide Catalyst. Biochem. J. 2013, 454 (Pt 2), 181–190. https://doi.org/10.1042/BJ20130360.

(19)      Katchman, B. A.; Ocal, I. T.; Cunliffe, H. E.; Chang, Y.-H.; Hostetter, G.; Watanabe, A.; LoBello, J.; Lake, D. F. Expression of Quiescin Sulfhydryl Oxidase 1 Is Associated with a Highly Invasive Phenotype and Correlates with a Poor Prognosis in Luminal B Breast Cancer. Breast Cancer Res. 2013, 15 (2), R28. https://doi.org/10.1186/bcr3407.

(20)      Sung, H.-J.; Ahn, J.-M.; Yoon, Y.-H.; Na, S.-S.; Choi, Y.-J.; Kim, Y.-I.; Lee, S.-Y.; Lee, E.-B.; Cho, S.; Cho, J.-Y. Quiescin Sulfhydryl Oxidase 1 (QSOX1) Secreted by Lung Cancer Cells Promotes Cancer Metastasis. Int. J. Mol. Sci. 2018, 19 (10). https://doi.org/10.3390/ijms19103213.

(21)      Antwi, K.; Hostetter, G.; Demeure, M. J.; Katchman, B. A.; Decker, G. A.; Ruiz, Y.; Sielaff, T. D.; Koep, L. J.; Lake, D. F. Analysis of the Plasma Peptidome from Pancreas Cancer Patients Connects a Peptide in Plasma to Overexpression of the Parent Protein in Tumors. J. Proteome Res. 2009, 8 (10), 4722–4731. https://doi.org/10.1021/pr900414f.

(22)      Portes, K. F.; Ikegami, C. M.; Getz, J.; Martins, A. P.; de Noronha, L.; Zischler, L. F.; Klassen, G.; Camargo, A. A.; Zanata, S. M.; Bevilacqua, E.; et al. Tissue Distribution of Quiescin Q6/Sulfhydryl Oxidase (QSOX) in Developing Mouse. J. Mol. Histol. 2008, 39 (2), 217–225. https://doi.org/10.1007/s10735-007-9156-8.

(23)      Coppock, D.; Kopman, C.; Gudas, J.; Cina-Poppe, D. A. Regulation of the Quiescence-Induced Genes: Quiescin Q6, Decorin, and Ribosomal Protein S29. Biochem. Biophys. Res. Commun. 2000, 269 (2), 604–610. https://doi.org/10.1006/bbrc.2000.2324.

(24)      Pernodet, N.; Hermetet, F.; Adami, P.; Vejux, A.; Descotes, F.; Borg, C.; Adams, M.; Pallandre, J.-R.; Viennet, G.; Esnard, F.; et al. High Expression of QSOX1 Reduces Tumorogenesis, and Is Associated with a Better Outcome for Breast Cancer Patients. Breast Cancer Res. 2012, 14 (5), R136. https://doi.org/10.1186/bcr3341.

(25)      Ferdosi, S.; Ho, T. H.; Castle, E. P.; Stanton, M. L.; Borges, C. R. Behavior of Blood Plasma Glycan Features in Bladder Cancer. PloS One 2018, 13 (7), e0201208. https://doi.org/10.1371/journal.pone.0201208.